Today’s Research Reports on Trending Tickers: GW Pharmaceuticals and Teva Pharmaceutical Industries
Progress of the recent tax bill hit a snag on Thursday as two GOP Senators raised some concerns. All sectors closed down on Thursday dragging markets lower, with the Healthcare and Materials contributing most losses. The Dow Jones Industrial Average declined 0.31 percent to close at 24,508.66, while the S&P 500 Index fell 0.41 percent to close at 2,652.01. The Nasdaq Composite Index decreased 0.28 percent to close at 6,856.53.
“This market has been going in lockstep with the progress made in the tax bill,” said Art Hogan, chief market strategist at B. Riley FBR. “When you see bumps in the road, you’re going to get some volatility.”
RDI Initiates Coverage on:
GW Pharmaceuticals Plc
Teva Pharmaceutical Industries Ltd.
GW Pharmaceuticals stock jumped 5.52% Thursday, to close the day at $130.82. The stock recorded a trading volume of 955,572 shares, which was above its three months average volume of 392,095 shares. The Company announced on Wednesday that it has now reacquired full ownership of the development and commercialization rights to Sativex® (nabiximols) in the U.S. In the last year, GW Pharmaceuticals shares have traded in a range of 92.65 – 136.95. The share price has gained 41.20% from its 52 week low. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $116.48 is greater than its 200-day moving average of $108.42. Shares of GW Pharmaceuticals have gained roughly 16.86 percent in the past month and are up 17.06 percent year-to-date.
Access RDI’s GW Pharmaceuticals Plc Research Report at:
On Thursday, shares in Teva Pharmaceutical Industries recorded a trading volume of 113,802,068 shares, which was above the three months average volume of 24,130,393 shares. The stock ended the day 10.19% higher at 17.30. The company has announced a restructuring plan wherein it will cut almost 25% of its workforce. The share price has gained 59.45% from its 52 week low with a 52 week trading range of 10.85 – 38.31. The company’s shares are currently trading below their 200-day moving average. The stock’s 50-day moving average of $13.70 is below its 200-day moving average of $20.85. Shares of Teva Pharmaceutical have gained roughly 47.23 percent in the past month and are down 52.28 percent year-to-date.
Access RDI’s Teva Pharmaceutical Industries Research Report at:
Our Actionable Research on GW Pharmaceuticals Plc (NASDAQ:GWPH) and Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.